If you’re 50 or older, there’s a new kind of flu shot this year: How it works and where to get it
FDA approved Moderna's Mflusiva, an mRNA flu vaccine, for adults 50+. It reduces flu risk by 26.6% vs. standard shots but has more side effects. Medicare covers it. Moderna must track safety long-term. Availability may be limited.
How this was made
The 30-second read
Why it matters
The approval could diversify Moderna's product portfolio beyond COVID‑19, adding a seasonal revenue source and enhancing its reputation in mRNA technology.
Market read
Regulatory clearance of a new mRNA flu vaccine is a material event for Moderna and may influence the broader biotech and vaccine markets.
What to watch
Manufacturing scale‑up and insurance reimbursement policies will determine actual revenue impact.
Background
Moderna's first mRNA flu shot, Mflusiva, received FDA approval, offering a novel egg‑free vaccine for adults 50 and older.
Ticker impact
FDA approved Moderna's mRNA flu vaccine Mflusiva for adults 50+ on Aug. 5, a first-of-its-kind product for the 2026‑27 season.
potential upward pressure as investors price in future sales and market share gains
Regulatory clearance is a material catalyst for a biotech; the product targets a large, aging population and fills a gap in flu vaccine technology.
Market effects
May boost the broader mRNA vaccine sector and encourage competitors to pursue similar flu vaccine programs.
U.S. flu vaccine market could see a shift toward mRNA products, affecting domestic manufacturers.
Sets a precedent for mRNA flu vaccines worldwide, potentially influencing regulatory approaches in other markets.
Counterpoint
If uptake is slow due to supply constraints or safety concerns, the stock could face disappointment.
Key entities
- companyModerna Inc.
Developer of the newly approved Mflusiva flu vaccine.
- regulatorFood and Drug Administration
U.S. agency that granted approval for the vaccine.
